NCT06800131View on ClinicalTrials.gov

Hepatitis B Vaccine Delivered Trans-dermally by MAP

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 5, 2025

Primary Completion Date

August 5, 2026

Study Completion Date

November 5, 2026

Conditions
Hepatitis B Vaccine
Interventions
DEVICE

Hepatitis B Vaccine administered trans-dermally via Microneedle Array Patch (MAP)

A total of 40 subjects will be enrolled, 30 subjects administered trans-dermally via Microneedle Array Patch (MAP).

BIOLOGICAL

Active comparator vaccine via intramuscular injection

10 subjects administered with active comparator vaccine via intramuscular injection.

All Listed Sponsors
collaborator

QuadMedicine

INDUSTRY

lead

International Vaccine Institute

OTHER